Simtra Biopharma Solutions Capabilities Update October 2026: Fill Finish

Demand for sterile injectable manufacturing continues to grow, making capacity, flexibility, and supply resilience increasingly important when selecting a CDMO partner. Simtra is expanding its global manufacturing network with new vial and pre-filled syringe lines, additional lyophilization capacity, and highly potent manufacturing capabilities across the U.S. and Europe.

These investments include high-speed pre-filled syringe filling, flexible vial processing, advanced isolator technology, and dedicated capacity for ADCs and other highly potent therapies. With development and manufacturing capabilities located on established campuses, customers can access support across clinical development, scale-up, and commercial manufacturing.

Explore how Simtra’s expanding sterile manufacturing footprint is designed to give pharmaceutical companies more options as programs evolve. Watch the webinar to see what’s next.